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Abstract
In this study we investigated if and how cannabinoid receptor stimulation regulates macrophageal differentiation,
which is one of the key steps in the immune effector reaction. For that reason, we used a well established
differentiation model system of human U937 myelocytic leukemia cells that differentiate along the monocyte/
macrophage lineage upon stimulation with the phorbol ester PMA. Constant cannabinoid receptor (CB) stimulation
was performed using WIN55212-2, a potent synthetic CB agonist. We found that WIN55212-2 inhibited CB1/2-
receptor-dependent PMA-induced differentiation of human myelocytic U937 cells into the macrophageal
phenotype, which was associated with impaired vimentin, ICAM-1 and CD11b expression. In the presence of
WIN55212-2, cdc2 protein and mRNA expression was progressively enhanced and Tyr-15-phosporylation of cdc2
was reduced in differentiating U937 cells. Additionally, p21
Waf1/Cip1 expression was up-regulated. PMA-induced
apoptosis was not enhanced by WIN55212-2 and differentiation-associated c-jun expression was not altered. In
conclusion, we suppose that WIN55212-2-induced signals interferes with cell-cycle-arrest-signaling in differentiating
myelocytic cells and thus inhibits macrophageal differentiation. Thus, it is possible that the cannabinoid system is
able to influence one of the key steps in the immune effector function, the monocytic-macrophageal
differentiation by alteration of cell cycle control proteins cdc2 and p21, and is therefore representing a promising
option for therapeutic intervention in exacerbated immune reactions.
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Introduction
Cannabinoids have been used as medicinal plant
extracts for a long time. Already 4000 years ago, the
Chinese emperor successfully treated diseases associated
with increased immune reaction and inflammation using
plant extracts [1]. The fact that the signaling pathways
of the cannabinoid system are conserved throughout
various species suggests an evolutionary benefit [2,3].
Cannabinoid signals can be mediated by different recep-
tors, the first cannabinoid receptor CB1 was discovered
in 1990 in the brain. A few years later a second receptor
CB2 was cloned from immune cells [4,5]. The activation
of CB1 and CB2 results in different cellular responses:
(i) inhibition of adenylyl cyclase and the cAMP/protein
kinase A (PKA)-dependent pathway by inhibitory G-pro-
teins (Gi) which leads to a reduced production of cAMP
[6] while recent research suggests that these receptors
can also stimulate cAMP production by directly stimu-
lating G-proteins (Gs) [7] (ii) stimulation of mitogen-
activated protein kinase (MAPK) cascade, especially the
extracellular signal kinase (ERK) [8] and the p38 MAPK
cascade [9]. Whereas the CB1 receptor is mainly, but
not exclusively, expressed on neurons, the CB2 receptor
is primarily present in immune cells [8,10]. Other recep-
tors in the cannabinoid signal system include the
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tein-coupled receptor 55, also known as GPR55 [12,13].
Interestingly, many cannabinoid-related compounds
have little if any affinity for either of the two known
cannabinoid receptors CB1 or CB2 - suggesting that
other unidentified receptors might be involved. The
endogenous ligands for the endocannabinoid system are
anandamide (AEA), 2-Arachidonylglycerol (2-AG), nola-
din ether and virodhamine, but fast degradation of these
substances by the specific monoglyceride lipase (in the
case of 2-AG), serine hydrolase and fatty acid amide
hydrolase (for AEA and 2-AG) limits the usage of these
ligands for the study of the signaling pathways [14,15].
Therefore stable, non-degradable synthetic cannabinoids
such as CP55940, HU210 (CB1) and WIN55212-2 (CB1/
CB2) are often used for the analysis of signaling path-
ways and molecules [16,17]. In our study, we used
WIN55212-2 ((R)-(+)-[2, 3-Dihydro-5-methyl-3-(4-mor-
pholinylmethyl)pyrrolo[1, 2, 3-de)-1, 4-benzoxazin-6-yl]-
1-napthalenylmethanone mesyalate), a potent aminoalk-
ylindole cannabinoid (CB) receptor agonist for human
CB1 and CB2 receptors, in micromolar concentrations
as described in other cellular studies [18].
Different cannabinoids have been shown to influence
the functional activities of various immune cells in
r o d e n t sa sw e l la si nh u m a n s ,including B lymphocytes,
T lymphocytes, natural killer cells and macrophages
[18-22]. In these studies, cannabinoids demonstrated
pleiotropic effects on cells of the immune system such
as suppressed T cell proliferation, inhibited antibody
response, enhanced B cell growth, various effects on
macrophages and their functionality as well as inhibition
of cytokines and a switch from inflammatory to anti-
inflammatory cytokine subtypes [17,21]. Recently, it was
shown that CB2 mediated immunosuppressive activities
of AEA in primary T lymphocytes, including Th-17
cells, an important finding in the light of new endocan-
nabinoid-based immunotherapeutic approaches [19].
CB2 receptors are widely expressed in cells of the
immune system such as in monocytes/macrophages, B
cells, NK cells, and T cells [20-22]. General mechanisms
by which cannabinoid receptor activation is considered
to act immunosuppressive (for a review see [21] are for
example 1.) decreasing the expression of cAMP-respon-
sive genes by inhibition of cAMP/protein kinase A
(PKA) pathway, 2.) enhancement of apoptotic genes
regulated by NF-kappaB by phosphorylation of IkappaB-
alpha, 3.) PPARgamma-dependent inhibition of NF-AT
activation or 4.) interference in the cell cycle by activa-
tion of p21
waf-1/cip-1 and induction of a G0/G1 phase
arrest. Cannabinoids seem to control immune function
by interfering at different points and key mechanisms of
the orchestrated immunological network: CB2-mediated
inhibition of TNF-alpha, IL-1beta, IL-6 and IL-8 release
by monocytes/macrophages, Th1- to Th2-type cytokine
shift in T cells, as wells as suppression of IFN-g and IL-
12 release.
Cells of the monocyte-macrophage-system constantly
patrol the organism, transmigrate trough the blood ves-
sels and into the tissues, whe r et h e yd i f f e r e n t i a t ei n t o
the macrophageal phenotype, a phagocytosing immu-
noeffector cells, which also presents antigens towards T
cells. Cannabinoid receptor agonists are known to sup-
press macrophage functions such as phagocytosis, bac-
tericidal activity, NO production and cell migration
[21,23-25].. However, it is still not known if and how
cannabinoid receptor stimulation regulates macropha-
geal differentiation, which is one of the key steps in the
immune effector reaction. For that reason, we used a
well established differentiation model system of human
U937 myelomonocytic leukemia cells that allows investi-
gation of differentiation-dependent alterations [26-29].
Treatment of U937 cells with phorbol-12-myristate-13-
acetate (PMA) is accompanied by growth arrest and
induction of a differentiation program, in which the
cells acquire a variety of morphological and functional
changes associated with macrophages.
Materials and methods
Cell culture
U937 (human, myelocytes) cells were obtained from
American Tissue and Cell Culture (ATCC) and cultured
in RPMI-1640 with 10% of fetal calf serum (FCS) and
1% of stable glutamine (all Biochrom, Germany) at 37°C
u n d e rn o r m o x i a( a i rp l u s5 %C O 2)i nah u m i d i f i e d
atmosphere. Cells were seeded at a density of 0.2 × 10
6
cells/ml and were subcultured upon reaching 1, 0 × 10
6
cells/ml. Medium was changed every 2 to 3 days. Cells
were counted using Neubauer chamber and trypan blue
(Sigma-Aldrich) was used for viability determination.
Differentiation
For differentiation of U937 myelocytic cells into a
monocyte/macrophage-like phenotype, the cells were
treated with 25 nM phorbol-12-myristate-13-acetate
(PMA) (Sigma-Aldrich) for 72 hours at a densitiy of 0.5
×1 0
6 cells/ml. PMA was diluted in DMSO (Sigma-
Aldrich), the concentration of DMSO was 1:1000 at all
times in every group. Control cells were incubated with-
out PMA, but in 1:1000 DMSO. The share of differen-
tiated cells was measured at the time points of 24, 48
and 72 hours. Cells were collected by gently scraping
(cell scraper) in culture medium, centrifuged for 8 min
at 300 g and the supernatant was removed. Cell pellets
were washed twice in ice cold PBS and directly analyzed
( v i a b i l i t y ,f l o wc y t o m e t e r )o rs t o r e da t- 8 0 ° Cf o rf u r t h e r
analysis (immunoblotting, qRT-PCR). Optimal PMA
concentration was selected by determining the
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preliminary experiments, viability of U937 cells has been
tested in the presence of PMA concentrations up to 200
nM and of WIN55212-2 concentrations up to 10 μM.
Treatment of U937 cells with PMA results in a decrease
of viability in the non-adherent cell fraction after 2 h,
whereas WIN55212-2 exhibited no toxicity up to a con-
centration of 5 μM and 72 h incubation (viability >
90%). Inhibition of cannabinoid type 1 (CB1) and type 2
(CB2) receptors was performed by co-incubation with 2
μM AM251 (CB1-inhibition) and/or 2 μM AM630
(CB2-inhibition).
Viability Assays (MTT and annexin V/propidium iodide
FACS)
Cytotoxicity was measured by 3-(4, 5-dimethylthiazol-2-
yl)-2, 5- diphenyltetrazolium bromide (MTT) assay and
annexin V/propidium iodide (PI) staining for apoptosis/
necrosis. Different WIN55212-2 concentrations (2-10
μM) and 25 nM PMA were added simultaneously or
separately to the cell culture. Viability (MTT-assay) and
percentage of apoptosis/necrosis (flow cytometry analy-
sis; annexin V/propidium iodide) were measured at dif-
ferent time points (30 min-72 h). Phosphatidylserine
exposure and propidium iodide incorporation was
assessed using the annexinV-FLUOS staining kit
(Roche) following manufacturer’s instructions. U937
cells were treated separately with PMA or simulta-
neously with PMA/WIN55212-2 and gently scraped in
medium afterwards. Cells were collected and washed in
PBS followed by 15 min staining with annexin V/propi-
dium iodide solution at room temperature and analyzed
by flow cytometry (Becton Dickinson, Basel, Switzer-
land). For immunocytochemical analysis of apoptotic
cells, cells were stained with annexin V and DAPI after
fixation with 3% paraformaldehyde and 2% sucrose in
PBS and analyzed by microscopy.
Staining and FACS analysis of ICAM-1 and CD11b
Different WIN55212-2 concentrations (3-5 μM), 25 nM
PMA and CB1 (2 μM AM251) or CB2 (2 μMA M 6 3 0 )
inhibitor were added simultaneously or separately to the
cell culture. U937 cells were treated separately with
PMA, simultaneously with PMA/WIN55212-2 or simul-
taneously with PMA/WIN55212-2 and AM251 or
AM630 and gently scraped in RPMI-1640 medium after-
wards. Cells were collected and washed in PBS followed
by 30 min staining with ICAM-1-PE (BD Bioscience),
CD11b-APC (BD Bioscience) and SYTOX AADvanced
(Invitrogen; staining of dead cells, dead cells were not
calculated). Staining procedure was according to the
manufacturer’s protocols. Cells were analyzed immedi-
ately after staining by flow cytometry (FACS Canto II,
Becton Dickinson, Basel, Switzerland).
Detection of cell cycle control proteins by immunoblot
analysis
Total protein lysates were produced with an ice cold
hypotonic lysis buffer composed of Tris (50 mM),
EDTA (10 mM), Na3VO4 (1 mM), NaF (10 mM), NaCl
(165 mM), 1 mM PMSF, with 1% Triton-X 100 and 1
mM protein inhibitor cocktail (Sigma-Aldrich). Cells
were incubated for 15 min in lysis buffer on ice, fol-
lowed by 25s sonication at 50% intensity. Lysates were
continuously shaken for 10 min and then centrifuged at
14, 000 rpm for 10 min at 4°C. Pellets were removed
and protein concentration was determined using BCA
protein kit (Pierce). Supernatants were stored at -80°C.
Aliquots of lysates were incubated in 50% glycerol
(Sigma-Aldrich), 5% 2-mercaptoethanol (Fluka), and
0.5% bromophenol blue (Sigma-Aldrich), boiled for 5
min and centrifuged shortly. Proteins were separated in
12% SDS-polyacrylamide gels (Fluka). Each lane was
loaded with 40 μg protein extract. Separated proteins
were transferred in 20% Tris-methanol buffer onto a
nitrocellulose membrane (Pierce) and blocked with Li-
Cor blocking buffer (Biochrom) diluted 1:1 with PBS
(Biochrom) for 2 hours. Membranes were stored
between filter papers at -20°C. After thawing, mem-
branes were washed in TBS-Tween (0, 1%) for 10 min
(Sigma-Aldrich) and then incubated with polyclonal
antibodies against cdc2, cdc2
Tyr15,c d c 2
Thr161,c h k 1 ,p -
chk1, c-jun, GAPDH (all from Cell Signaling) as well as
actin and vimentin (both from Sigma) overnight at 4°C
using dilutions as described in the appropriate data-
sheets. Specific binding of the primary antibodies was
detected by corresponding secondary infrared dye-con-
jugated anti-mouse IgG antibodies, incubated at room
temperature for 2 hours in Li-Cor blocking buffer (Li-
Cor) 1:1 diluted with PBS (Biochrom) and visualized by
an Odyssey infrared imaging system (Li-Cor Bios-
ciences). Intensities were calculated as percentage of
band signals detected by the Li-Cor system relative to
non-induced control cells. For normalization between
different blot membranes, an internal control (S0) has
been used. Additional staining of the membranes with
actin and GAPDH, dependent of the size of the primary
detected protein, was used as loading control.
Vimentin-, Actin- and DAPI-staining for microscopic
analysis
U937 cells were treated with PMA or with PMA/
WIN55212-2 and gently scraped in medium afterwards.
Cells were collected and washed in PBS followed by
fixation with 3% paraformaldehyde and 2% sucrose in
PBS and attached onto glass slides by cytospin. Samples
were permeabilized with 0.2% Triton-X 100 in PBS for 5
min at RT followed by incubation with rabbit-anti-
vimentin antibody (1:200, Abcam) in 2% BSA in PBS at
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anti rabbit FITC-labelled antibody at a 1:200 dilution
(Jackson immune research), phalloidin-texas red (1:50)
(molecular probes) and 1 μg/ml DAPI (Molecular
p r o b e s )i nP B Sf o r1ha tR T .S a m p l e sw e r et h e n
embedded in fluorescence mounting medium (Dako)
and analyzed using a confocal laser scanning microscope
(SP2, Leica, Heidelberg, Germany).
Quantitative real-time PCR analysis (qRT-PCR)
Total RNA was extracted from 2-5 × 10
6 cells using the
RNeasy Mini Kit Isolation System (Qiagen, Hombrechti-
kon) and DNA was removed using the RNase-Free
DNase Set (Qiagen, Hombrechtikon) according to the
manufacturer’s protocols. One hundred ng of RNA was
transcribed with SuperScript First-Strand Synthesis Sys-
tem for RT-PCR (Invitrogen,) in a 20 μl reaction volume
according to the manufacturer’s instruction for First-
Strand cDNA Synthesis using Oligo(dT). The relative
expression of genes was determined using FAM-labeled
TaqMan Gene Expression Assays (Applied Biosystems)
for cdc2 (Hs00938777_m1), p21 (Hs99999142_m1), CB1
(Hs01038522_s1), CB2 (Hs00361490_m1) and glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) as house-
keeping gene expression control (Hs99999905_m1).
Quantitative real-time PCR (qRT-PCR) was performed
using 0.2 μlo fc D N Ai na2 0μl reaction volume con-
taining 5 μl TaqMan Gene Expression Master Mix in
MicroAmp Fast Optical 96-Well Reaction Plates. Sam-
ples were run on an ABI 7500 Fast Real-Time-PCR sys-
tem (Applied Biosystems), thermal cycling conditions
were 50°C for 2 min followed by 95°C for 10 min and
40 cycles of 95°C for 15 s and 60°C for 1 min. The rela-
tive quantification of gene expression was performed
using the comparative CT method (DDCt). All reagents
and devices for quantitative real time PCR were pur-
chased from Applied Biosystems (Rotkreuz,
Switzerland).
Statistical analysis
For statistical analysis the non-parametric Mann-Whit-
ney test was used. All experiments were performed in
minimum in triplicate at three different time points at
three independent days (n = 3, triplets). p < 0.05 was set
as significance level.
Results
WIN55212-2 inhibited differentiation of human monocytic
U937 cells into an adherent phenotype
To study the effect of cannabinoid receptor stimulation
on macrophageal differentiation, we used a well charac-
terized differentiation system of human myelocytic U937
cells [26-29], which can be induced by phorbol ester to
differentiate into adherent macrophage-like cells
paralleled by a cell cycle arrest of the autonomously
proliferating tumor cells.. For this purpose, proliferating
U937 cells were incubated with PMA alone or together
with WIN55212-2. Differentiation was tracked by deter-
mining the share of differentiated and cell cycle-arrested
adherent cells and the share of non-differentiated prolif-
erating suspended cells at defined points from 24 h up
to 72 h after addition of PMA and/or WIN55212-2 by
FACS counting.
PMA clearly induced U937 cell differentiation with a
pronounced increase of adherent cells within the first 24
h (Figure 1a). In the presence of WIN55212-2, PMA-
induced differentiation of U937 cells was severely
impaired and adherent cells were reduced to nearly half
of the non-treated group during all time points (Figure
1a). In parallel to the differentiation process, non-adher-
ent U937 cells disappeared continuously from the cul-
ture medium (Figure 1b). Consistently with the
decelerated adhesion of differentiating U937 cells after
PMA-induction, the additionally WIN-exposed U937
cells persisted longer and in higher concentrations in
the cell culture supernatant (Figure 1b).
Inhibition of macrophageal differentiation of human
U937 cells by WIN55212-2 was CB1- and CB2-receptor-
dependent
We investigated, if the inhibition of PMA-induced
macrophageal differentiation of U937 cells was depen-
dent on cannabinoid receptor type 1 (CB1) or type 2
(CB2) activity and incubated PMA/WIN55212-treated
U937 cells with the CB1 receptor inhibitor AM251 and/
or the CB2 receptor inhibitor AM630. Both CB1 and
CB2 receptor inhibition restored the differentiation pro-
cess as demonstrated by a significant increase of adher-
ent cells after 24 h incubation with PMA/3 μM
WIN55212 (Figure 2a) and a significant increase of
adherent cells after 24-72 h incubation with PMA/5 μM
WIN55212 (Figure 2b). Thus, the inhibitory action of
WIN55212-2 on macrophageal differentiation of U937
cells is CB1- and CB2-receptor-dependent.
WIN55212-2 did not enhance PMA-induced apoptosis
Since it is well known that cannabinoid receptor stimu-
lation may induce apoptosis in different cell types of the
immune system [21], we first investigated whether incu-
bation with WIN55212-2 drives proliferating U937 cells
into apoptosis upon induction of differentiation by
PMA, therefore subsequently reducing the number of
differentiated cells. As demonstrated in Figure 3a,
WIN55212-2 did not enhance PMA-induced apoptosis
in U937 cells, but in contrast protected significantly
non-differentiated cells from apoptosis at a concentra-
tion of 3 μM at all time points (Figure 3a). Additional
immunocytochemical analysis of U937 cells after 72 h
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WIN55212-2 showed less annexin V-positive cells in the
WIN55212-2-cotreated group (Figure 3b), which sup-
ported also visually the results of the FACS analysis
(Figure 3a). In the DMSO control group, no annexin V
positive apoptotic cells could be detected. Annexin V-
staining of adherent cells revealed only a few apoptotic
cells in this differentiated U937 cell fraction (Figure 3c).
FACS analysis after propidium iodide staining demon-
strated no differences in all cell fractions, but only a
slightly higher percentage of propidium iodide positive
cells in the PMA-differentiated U937 cell fraction, most
probably due to cell scraping during harvest (data not
shown).
WIN55212-2 impaired vimentin expression in PMA-
induced U937 cells
One of the most prominent alterations during macro-
phageal differentiation of U937 cells is the reorganiza-
tion of the cytoskeleton. Thus, we investigated
cytoskeletal changes by actin- and vimentin staining
after 72 h incubation with PMA with/without
WIN55212-2 (Figure 4). Whereas actin expression and
intracellular distribution was not altered in all groups,
expression of vimentin was enhanced distinctly after
PMA treatment compared to the controls, but was
ameliorated by co-incubation with 3 μMo r5μM
WIN55212-2. Immunoblot analysis of vimentin
expression in PMA-induced U937 cells during differ-
ent time points of differentiation demonstrated a sig-
nificant reduction of vimentin protein expression
between 24 h to 72 h after the induction of differen-
tiation (Figure 5). As soon as vimentin protein rised
during the differentiation process after 24 h, its
increasing expression was ameliorated in WIN55212-
2-treated U937 cells. Since vimentin is highly
expressed during macrophageal differentiation [29],
the findings support an inhibitory effect of cannabi-
noid receptor stimulation on macrophageal differentia-
tion and cytoskeletal reorganization.
a b Adherent U937 Non-adherent U937
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Figure 1 WIN55212-2 inhibited differentiation of human monocytic U937 cells into an adherent phenotype. Differentiation of U937 cells
was induced by 25 nM PMA with or without co-incubation with WIN55212-2. The experimental groups were: 1.) Vehicle control = treatment
with 0.1% DMSO only, 2.) Differentiation control = treatment with 25 nM PMA, 3.) Experimental groups were treated additionally with 3 μMo r5
μM WIN55212-2, respectively. Adherent (figure 1a) and non-adherent cells (figure 1b) were separated and quantified after different time points
up to 72 h by FACS analysis. Percentage of control group at time point zero is shown. Data are shown as mean +/- SEM, n = 12; *p < 0.05 in
comparison with the PMA-treated group without WIN55212-2.
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Macrophageal differentiation is associated with a com-
plex regulation of different signal pathways and the
expression of differentiation-related transcription factors,
such as c-jun, which forms together with c-fos the AP-1
early response transcription factor, which in turn con-
trols a number of signal processes including differentia-
tion, proliferation, and apoptosis. C-jun is therefore
considered as one of the key molecules and an early and
rapid response marker of macrophageal differentiation
[28,29]. We therefore analysed c-jun protein expression
by immunoblotting, which was enhanced 4-fold after 2
h of PMA treatment (Figure 6a), much earlier than the
cellular reorganization commenced (Figure 4 and 5). C-
jun protein expression then returned to nearly control
levels after 24 h. No differences in c-jun protein expres-
sion could be detected in dependence of WIN55212-2-
treatment (Figure 6a). Thus, WIN55212-2-mediated
effects on macrophageal differentiation are likely inde-
pendent from c-jun expression.
WIN55212-2 altered expression and phosphorylation of
cell cycle control proteins
Induction of U937 cells differentiation with PMA results
predominantly in a G0/G1 and partly in a G2/M cell
cycle arrest without any detectable S phase cells [29-31].
For transition through the G2/M phase, phosphorylation
and dephosphorylation of different signaling molecules,
such as cdc2 and the cyclin dependent kinase 1 (cdk1)
are necessary. Because the entry into mitosis is regulated
by cdc2 kinase activation, which is controlled crucially
by dephosphorylation of cdc2 at Tyr15 and phosphory-
lation at Thr161 [32], we investigated the effect of
WIN55212-2 on cdc2 protein expression and phosphor-
ylation by immunoblotting. As demonstrated in Figure
6b, cdc2 protein expression increased between 24 h and
72 h after induction of differentiation. In the presence
of 5 μM WIN55212-2, cdc2 protein expression upon
PMA-treatment was enhanced significantly (Figure 6b).
During macrophageal differentiation, cdc2 was
strongly phosphorylated at Tyr15 (Figure 7a), which pre-
vents cells from entering into mitosis and contributes to
cell cycle arrest. In the presence of WIN55212-2, Tyr15-
phosphorylation of cdc2 was significantly and constantly
reduced between 24 h and 72 h after induction of differ-
entiation (Figure 7a). Additionally, Thr161-phosphoryla-
tion was not altered during PMA-induced macrophageal
differentiation and not influenced by WIN55212-2 (Fig-
ure 7b).
In order to investigate whether the enhanced cdc2
protein concentration is the result of an increased cdc2
transcription, we analyzed cdc2 mRNA concentration in
PMA-induced U937 cells in the presence of absence of
incubation with WIN55212-2. As demonstrated in Fig-
ure 8a, PMA-induced downregulation of cdc2 mRNA
expression was significantly ameliorated during addi-
tional WIN55212-2-treatment of U937 cells.
Additionally, we determined the mRNA expression of
the cell cycle regulatory protein p21
Waf1/Cip1,w h i c h
forms heterotrimeric complexes with cyclins and cyclin-
dependent kinases, inhibits CDK2 kinase activity and
blocks progression before the G1/S cell cycle check-
point. PMA induced a dramatic increase of p21
Waf1/Cip1
mRNA expression in U937 cells which is consistent
with differentiation-associated cell cycle arrest. In the
presence of WIN55212-2, up-regulation of p21
Waf1/Cip1
was distinctly ameliorated (Figure 8b). Taken together,
*
*
Adherent U937 a
*
*
**
**
* **
Adherent U937 b
Figure 2 WIN55212-2-mediated inhibition of differentiation of
human monocytic U937 cells is CB1- and CB2-receptor-
dependent. Differentiation of U937 cells was induced by 25 nM
PMA in the presence of 3 μMo r5μM WIN55212-2 (figure 2a or
figure 2b, respectively) with or without co-incubation with 2 μM
AM251 (CB1-inhibition) and/or 2 μM AM630 (CB2-inhibition).
Adherent cells were separated and quantified after different time
points up to 72 h by FACS analysis. Percentage of control group at
time point zero is shown. Data are shown as mean +/- SD, n = 8;
*p < 0.05, **p < 0.01, ***p < 0.001 in comparison with the PMA/
WIN55212-2 -treated group without CB1- or CB2-inhibition.
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phosphorylation of PMA-induced cell cycle control pro-
teins such as cdc2 and p21 (Figure 8ab).
No downregulation of CB1 and CB2 mRNA expression by
WIN55212-2
Because feedback-regulation is a common and frequent
principle in cells of the immune system, we investigated
the influence of WIN55212-2 on CB1 and CB2 expres-
sion during PMA-induced macrophageal differentiation
of U937 cells (Figure 9). We detected an increase in
CB1 mRNA expression in the presence of WIN55212-2,
which was enhanced by parallel inhibition of CB2 recep-
tors (Figure 9a). The detected changes in CB2 mRNA
expression were not significant (Figure 9b). Also, the
elevation of CB1 mRNA in differentiating U937 cells
was not significant compared to undifferentiated con-
trols (Figure 9a).
CB1 and CB2 receptor-dependent down-regulation of
ICAM-1 and CD11b in WIN55212-2 treated differentiating
U937 cells
Finally, we investigated the effect of WIN55212-2 on
ICAM-1 and CD11b expression in differentiating U937
cells. We found that ICAM-1 was up-regulated in differ-
entiating U937 cells, which was distinctly reduced by
co-incubation with 5 μM WIN55212-2 (Figure 10a).
Reduction of differentiation-associated ICAM-1 up-regu-
lation was less pronounced after inhibition of CB1 and
CB2 receptors (Figure 10b). The expression of CD11b
demonstrated a similar effect: Whereas CD11b was
induced in differentiating U937, it was reduced by 5 μM
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Figure 3 WIN55212-2 did not enhance PMA-induced apoptosis. Differentiation of U937 cells was induced by 25 nM PMA with or without
co-incubation with WIN55212-2. The experimental groups were: 1.) Vehicle control = treatment with 0.1% DMSO only, 2.) Differentiation control
= treatment with 25 nM PMA, 3.) Experimental groups were treated additionally with 3 μMo r5μM WIN55212-2, respectively. Differentiated (a)
and non-differentiated cells (b) were separated due to its adherence after 72 h incubation and apoptotic cells were detected by annexin V
staining and FACS analysis (figure 3a) or immunocytochemical analysis after counterstaining with DAPI (figure 2b). Annexin V-positive cells in the
non-differentiated cell fraction are quantified in figure 3a and displayed in figure 3b. Immunocytochemical analysis of adherent cells are shown
in figure 3c. Data are shown as mean +/- SEM, n = 12; *p < 0.05 in comparison with the total cell number. Scale bar = 10 μm.
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Page 7 of 16WIN55212-2 (Figure 10c) in a CB1- and CB2-receptor-
dependent manner.
Discussion
In our study we demonstrated that the cannbinoid
receptor agonist WIN55212-2 inhibited macrophageal
differentiation CB1- and CB2-receptor-dependent in a
well established monocyte-macrophageal differentiation
model. Inhibition of macrophageal differentiation by
WIN55212-2 was associated with impaired vimentin
expression, enhanced cdc2 protein and mRNA expres-
sion and reduced Tyr-15-phosporylation of cdc2 upon
PMA-induction.
Previous studies have shown that the incubation with
PMA of human leukemic cell lines like myelocytic U937
(also e.g. monocytic THP1 and promyelocytic HL60)
induced a differentiation along a phagocytic lineage.
This led to growth inhibition, cell cycle arrest, adher-
ence, expression or upregulation of differentiation-asso-
ciated molecules like the cytoplasmic intermediate
filament vimentin or the transcription factor c-jun, as
well as activation and deactivation of different signaling
molecules like cdk1, cdk2, c-fos and others
[26-29,33,34]. Moreover, it was reported that the mor-
phology and a variety of functional parameters do not
significantly change during PMA-induced differentiation
until the cells enter a retrodifferentiation program after
long term culture [27].. Therefore, influences on differ-
entiation and maturation of U937 cells are likely to take
place within the first three days of PMA treatment.
Vimentin Actin DAPI merged
a b c d
ef gh
ijk l
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PMA
PMA
3μM WIN
PMA
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control
Figure 4 Immunocytochemical analysis of vimentin expression in PMA-induced U937 cells co-incubated with WIN55212-2.
Differentiation of U937 cells was induced by 25 nM PMA with or without co-incubation with WIN55212-2. The experimental groups were: 1.)
Vehicle control = treatment with 0.1% DMSO only (a, b, c, d), 2.) Differentiation control = treatment with 25 nM PMA (e, f, g, h), 3.) Experimental
groups were treated additionally with 3 μM (I, j, k, l) or 5 μM (m, n, o, p) WIN55212-2, respectively. Cells were stain against vimentin (a, e, i, m),
actin (b, f, j, n) and DAPI (c, g, k, o) and analysed by confocal laser scanning microscopy. Merged pictures are shown (d, h, l, p). Scale bar = 15
μM.
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Page 8 of 16Thus, we aimed to investigate the influence of sustained
cannabinoid-receptor-stimulation using the synthetic
and stable cannabinoid receptor agonist WIN55212-2
on PMA-induced differentiation of human myelocytic
U937 cells into a macrophage-like phenotype and to
address the changes of molecular architecture possibly
involved in this process.
First, we investigated changes in protein expression
pattern of the cytoplasmic intermediate filament vimen-
tin, which has a strong influence during the differentia-
tion process to support cell adherence as well as
reorganization of cell structure and stabilizes the archi-
tecture of the cytoplasm [35]. We found that differentia-
tion-related vimentin-expression was ameliorated by
WIN55212-2. C-jun is a component of transcription fac-
tor AP-1 (activator protein 1), which activates the TRE/
AP-1 transcription element and plays a role in diverse
biological functions such as proliferation, differentiation
and apoptosis [36-38]. Both molecules are upregulated
after PMA treatment in U937 as well as in HL-60 and
THP-1 cells [26-29]. Since we detected no differences in
c-jun protein expression in dependence of WIN55212-
2-treatment, we suppose that cannabinoid-mediated
effects on macrophageal differentiation are independent
from c-jun expression.
Various studies showed that WIN55212-2 has pro-
apoptotic effects and results in growth arrest and down-
regulation of cell cycle dependent kinases like cdk2,
cdk4 and cdk6 in different tumor cell lines such as
HepG2 hepatoma cells [31]. In our study, we found that
WIN55212-2 did not enhance apoptosis in PMA-treated
U937 cells, but in contrast protected non-differentiated
U937 cells from apoptosis. Since PMA-induced apopto-
sis is mediated likely via an autocrine TNF-alpha feed-
back loop [39] and since it is known that cannabinoid
receptor stimulation inhibits TNF-alpha release in
monocytic cells [40], the anti-apoptotic effect of
WIN55212-2 in PMA-stimulated U937 cells could be
mediated via interference with autocrine TNF-alpha
secretion.
Because differentiation of U937 requires cell cycle
arrest, we investigated expression and phosphorylation
of the crucial cell cycle regulatory protein cdc2. Previous
studies in U937 cells demonstrated that the regulation
of cdc2 is cell-cycle-dependent, undetectable concentra-
tions of cdc2 in G1 but maximum expression of mRNA
and protein in G2/M transition were measured [28]. The
transition of eukaryotic cells into M-phase is regulated
by cdc2 kinase activation, a process controlled at several
steps including cyclin binding together with varying
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Figure 5 Immunoblot analysis of vimentin protein expression in PMA-induced U937 cells co-incubated with WIN55212-2. Differentiation
of U937 cells was induced by 25 nM PMA with or without co-incubation with WIN55212-2. The experimental groups were: 1.) Vehicle control =
treatment with 0.1% DMSO only (con), 2.) Differentiation control = treatment with 25 nM PMA (0), 3.) Experimental groups were treated
additionally with 3 μM (3) or 5 μM (5) WIN55212-2, respectively. Vimentin protein expression was analysed by immunoblotting and quantified
by Odyssey infrared imaging system (Li-Cor Biosciences) and shown as mean +/- SEM, n = 3. Relative intensities were normalized to a non-
induced control (S0) and a PMA-induced control (S1) which served as internal control for quantification if different blot membranes have been
used. *p < 0.05. One representative blot and one representative beta-actin control out of 3 is shown.
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Page 9 of 16protein levels and phosphorylation of cdc2 at Thr161,
Tyr14 and Tyr 15 position. The critical regulatory step
is the activation of cdc2 by dephosphorylation at Tyr14
and Tyr15 by the phosphatase cdc25 [32,41-44]. PMA
activates the calcium- and phospholipid dependent pro-
tein kinase C, but it is still unclear whether the activa-
tion of this enzyme contributes directly to the cell cycle
regulatory gene expression or if the introduction of the
differentiation process is responsible for the downregu-
lation of these genes [45]. The fact that other PKC acti-
vators like bryostatin 1 are considered to be a weaker
differentiation stimuli compared to PMA in U937,
resulting in a smaller p21 activation and cell cycle arrest,
strongly supports the second theory [46]. Nevertheless,
it could be shown that the expression of cdc2 and cdc25
mRNA is downregulated and cdc2 phosphorylation at
Tyr15 position is upregulated upon PMA treatment,
thus, resulting in a cell cycle arrest essential for the dif-
ferentiation process [28]. In our study, we detected an
enhanced cdc2 protein and mRNA expression associated
with reduced Tyr-15-phosporylation in differentiating
U937 cells treated with WIN55212-2.
Additionally, in the presence of WIN55212-2, differen-
tiation-induced up-regulation of p21
Waf1/Cip1 is distinctly
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Figure 6 Immunoblot analysis of c-jun and cdc2 protein expression in PMA-induced U937 cells co-incubated with WIN55212-2.
Differentiation of U937 cells was induced by 25 nM PMA with or without co-incubation with WIN55212-2. The experimental groups were: 1.)
Vehicle control = treatment with 0.1% DMSO only (con), 2.) Differentiation control = treatment with 25 nM PMA (0), 3.) Experimental groups
were treated additionally with 3 μM (3) or 5 μM (5) WIN55212-2, respectively. C-jun (figure 5a) and cdc2 (figure 5b) protein expression was
analysed by immunoblotting and quantified by Odyssey infrared imaging system (Li-Cor Biosciences) and shown as mean +/- SEM, n = 3.
Relative intensities were normalized to non-induced control cells (con) and an internal control (S0) for quantification if different blot membranes
have been used. *p < 0.05. One representative blot and one representative beta-actin control out of 3 is shown.
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Page 10 of 16ameliorated. p21
Waf1/Cip1 inhibits G1 cyclins and asso-
ciated cyclin-dependent kinases whereby induction of
p21
Waf1/Cip1 in most cell types is accompanied by a G0/
G1 cell cycle arrest. Expression of p21 is induced in a
p53-dependent manner after DNA damage. However,
after direct stimulation of PKC by PMA treatment the
elevation of p21 expression has been reported in a p53-
independent manner [46,47], which may support the
present model because of the non-functional p53 in the
U937 cells line. Additionally, in proliferating AGS and
MKN-1 gastric cancer cell lines, treatment with WIN
55, 212-2 induced p21
Waf1/Cip1 and arrested the cell
cycle in the G0/G1 phase, which was mediated via
activation of the MAPK pathway and inhibition of
pAKT [48]. Because in our experiments, we found an
ameliorated. p21
Waf1/Cip1 upregulation in PMA-induced
differentiating U937 cells, it can be assumed that WIN
55, 212-2 transmitted cell cycle arrest signals, which are
dependent on PKC-activation and probably on the cell
type and its proliferative state.
Our experiments suggest that stimulation of CB1/2
receptors by WIN55212-2 during macrophageal differ-
entiation did not downregulate CB1 and CB2 mRNA
expression and therefore did not activate a negative
feedback-loop during differentiation. In contrast, CB1
receptor expression was significantly upregulated in
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Figure 7 WIN55212-2 altered phosphorylation of cdc2 protein. Differentiation of U937 cells was induced by 25 nM PMA with or without co-
incubation with WIN55212-2. The experimental groups were: 1.) Vehicle control = treatment with 0.1% DMSO only (con), 2.) Differentiation
control = treatment with 25 nM PMA (PMA), 3.) Experimental groups were treated additionally with 3 μM (PMA + 3 μM WIN) or 5 μM (PMA +
5 μM WIN) WIN55212-2, respectively. Tyr15-cdc2 (figure 6a) and Thr161-cdc2 (figure 6b) phosphorylation was analysed by immunoblotting and
quantified by Odyssey infrared imaging system (Li-Cor Biosciences) and shown as mean +/- SEM, n = 3. Relative intensities were normalized to
non-induced control cells (con) and an internal control (S0) for quantification if different blot membranes have been used. *p < 0.05. One
representative blot and one representative beta-actin control out of 3 is shown.
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Page 11 of 16response to WIN55212-2 treatment during macropha-
geal differentiation. Therefore, we assume that the can-
nabinoid receptor systems maintains a constant
regulatory influence of cannabinoid receptor agonists
during macrophageal differentiation. In differentiating
macrophageal cells, CD11b and ICAM-1 are predomi-
nantly expressed and mediates inflammation by regulat-
ing leukocyte adhesion and migration and has been
implicated in several immune processes. We found that
WIN55212-2 reduced CB1- and CB2-receptor-depen-
dent the expression of CD11b and ICAM-1.
In conclusion, we suppose that WIN55212-2-mediated
CB1- and CB2-receptor-dependent signals reduce PMA-
mediated cell-cycle-arrest-signaling in maturating cells
along the monocytic lineage and therefore inhibit
macrophageal differentiation. Thus, it is possible that
the cannabinoid system is able to influence one of the
key steps in the immune effector function, the
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Figure 8 Quantitative real time PCR analysis of cdc2 and p21 mRNA expression in PMA-induced U937 cells co-incubated with
WIN55212-2. Differentiation of U937 cells was induced by 25 nM PMA with or without co-incubation with WIN55212-2. The experimental
groups were: 1.) Vehicle control = treatment with 0.1% DMSO only (con), 2.) Differentiation control = treatment with 25 nM PMA (0), 3.)
Experimental groups were treated additionally with 3 μM (3) or 5 μM (5) WIN55212-2, respectively. cdc2 (figure 7a) and p21 (figure 7b) mRNA
expression were analysed after different time points by quantitative real-time PCR. Data are shown as mean +/- SEM, n = 3. Relative expression
were normalized to GAPDH expression in non-induced cells. *p < 0.05.
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Figure 9 Quantitative real time PCR analysis of CB1 and CB2 receptor mRNA expression in PMA-induced U937 cells co-incubated with
WIN55212-2. Differentiation of U937 cells was induced by 25 nM PMA with or without co-incubation with WIN55212-2. The experimental
groups were: 1.) Vehicle control = treatment with 0.1% DMSO only (con), 2.) Differentiation control = treatment with 25 nM PMA (0), 3.)
Experimental groups were treated additionally with 3 μM (3) or 5 μM (5) WIN55212-2, respectively. One group was treated with 5 μM (5)
WIN55212-2 and 2 μM WIN AM630 (CB2 inhibition). CB1 (figure 9a) and CB2 (figure 9b) receptor mRNA expression were analysed after different
time points by quantitative real-time PCR. Data are shown as mean +/- SD, n = 3. Relative expression were normalized to GAPDH expression in
non-induced cells. *p < 0.05.
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Page 13 of 16monocytic-macrophageal differentiation by alteration of
cell cycle control proteins cdc2 and p21, and is therefore
representing a promising option for therapeutic inter-
vention in exacerbated immune reactions.
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